FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has completed dosing the first cohort of patients in its phase I clinical trial of Lucid-21-302 (Lucid-MS). According to the announcement, the study, which is being conducted by Lucid Psycheceuticals, the company’s wholly owned subsidiary, is the first-in-human study designed to evaluate Lucid-MS as a novel drug candidate for the treatment of multiple sclerosis (“MS”). A small molecule inhibitor of hypercitrullination, Lucid-MS is a patented first-in-class, new chemical entity (“NCE”) and a neuroprotective compound with a novel mechanism of action for the treatment of MS. The trial is a randomized, double-blind, placebo-controlled, single ascending dose (“SAD”) and multiple ascending dose (“MAD”) study. Outcomes of the study will determine the safety, tolerability and pharmacokinetics of Lucid-MS in healthy volunteers under fed and fasted conditions. “Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,” said Lucid Psycheceuticals CEO Dr. Lakshmi Kotra in the press release. “The safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled to say is expected to commence in the next few days.”
To view the full press release, visit https://ibn.fm/mvZaE
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultramicronized palmitoyl ethylamine (“PEA”) formulation for the treatment of inflammatory diseases. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds: Lucid-PSYCH and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit www.FSDPharma.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
